Clinical Study of Minocycline Hydrochloride Injectable Hydrogel for the Treatment of Periodontitis

Inclusion criteria

• Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.
• Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).
• Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.

Exclusion criteria

• Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c > 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.
• Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.
• Factors Interfering with Healing: Heavy smokers (average > 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.
• Special Physiological Periods: Pregnant or breastfeeding women.
• Drug Allergy: Known allergy to minocycline (MH), hyaluronic acid (HA), or similar chemical components.